Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company's principal business activity is developing, acquiring, in-licensing, out-licensing, marketing and distributing pharmaceutical products in Canada and internationally. The Company has a portfolio of products in various stages of development for various geographies that include Impavido, ATryn, Photofrin, FOCUSfactor, NXN-1882 (nNOS/5HT), NXN-4622 (nNOS) and nNOS/iNOS2 Inhibitor. Impavido (miltefosine) is a product for the treatment of leishmaniasis and is approved in 14 countries. Photofrin is a product for the treatment of oesophageal cancer, endobronchial cancer, high-grade dysplasia in Barrett's oesophagus and papillary bladder cancer and is in approved stage. FOCUSfactor is a product for dietary supplement and is in approved stage.